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Abstract 
Antibiotic resistant bacteria were first reported in the 1940s, several years after the clinical introduction of 
penicillin. Since then, antibiotic resistance has contributed to increasing bacterial infections, mortality rates, 
and treatment costs. One promising alternative to traditional antibiotics is the development and use of 
amphiphiles, compounds with at least one hydrophilic head group and one hydrophobic tail. Three novel 
series of triple-headed amphiphiles with variations in the third head group composition, tail length and 
number of tails (one or two) were synthesized. Isothermal titration calorimetry was used to determine the 
critical micelle concentration – the concentration at which amphiphiles aggregate and form micelles. The 
antibacterial activity of individual amphiphiles against six bacterial strains and of binary combinations 
against two representative strains was determined by standard antimicrobial microdilution techniques. The 
lowest concentration of amphiphile resulting in 50% hemolysis (EC50) was also determined.   
 
For all three amphiphiles series, log of the critical micelle concentration was inversely proportional to tail 
length. These series also shared a similar biological trend where antibacterial activity increased with tail 
length until an optimal tail length was reached (n = 12 for double-tailed amphiphiles; n = 18 for single-
tailed amphiphiles). Notably, three compounds (M-P,10,10; M-P,12,12; M-1,12,12) killed multiple 
bacterial strains at concentrations ranging from 1-16 µM and were not cytotoxic to blood cells, with EC50 
values that were two- to 65-fold higher than bactericidal concentrations. In addition, several combinations 
of amphiphiles exhibited synergistic antibacterial activity. These bactericidal, non-hemolytic amphiphiles 
could be useful in the medical field, especially when treating or preventing infection with antibiotic 
resistant pathogens.  
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Chapter 1: Introduction  
 
1.1 Significance 
More than two million Americans are infected with antibiotic resistant pathogens each year, resulting in the 
death of 23,000 infected individuals. 1 Infection with antibiotic resistant microorganisms can also inflate 
treatment costs and prolong the length of hospital stays. 2 One U.S. hospital reported the societal cost of 
antimicrobial-resistant infections (ARIs) in a single institution to be $13.35 million per year. The extension 
of hospital visits due to ARIs contributes to this cost, with estimates of prolonged hospital stays ranging 
from 6-12 days per patient.  2 
  
While reports of mortality rates and increased economic burden due to ARIs have brought attention to this 
crisis, antibiotic resistance is not a new phenomenon. Antibiotic resistance was reported as early as the 
1940s. Seven years after the introduction of penicillin in 1941, 50% of Staphylococcus aureus isolates were 
resistant to this antibiotic. 3 In fact, microorganisms usually acquire resistance to an antibiotic only a few 
years after the drug’s clinical introduction. 4,5 This rapid emergence of antibiotic resistance can be attributed 
to the mass use of antibacterial agents in healthcare institutes, communities, and the food industry. 6 
  
Hospitals are particularly prone to harboring antibiotic resistant organisms due to the frequent use of 
antibacterial agents and influx of infected patients. The frequencies of antibiotic resistance in pathogens 
that contributed to hospital-acquired infection (HAI) were estimated in a study performed by the National 
Healthcare Safety Network from 2006-2007. In this study, 56% of Staphylococcus aureus isolates were 
resistant to oxacillin; 13-19% of Pseudomonas aeruginosa isolates were resistant to extended-spectrum 
cephalosporins; and 33% of Enterococcus species were resistant to vancomycin. 7  
 
The presence of antimicrobial resistant pathogens in hospital patients and on equipment threatens modern 
clinical practices such as organ transplants, chemotherapy, infant care, and surgery. 1,8 Lack of effective 
antimicrobial treatments can lead to the spread of contaminants from equipment, healthcare employees, or 
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infected patients to uninfected patients. 9-14 Specific risk factors for HAIs include: stay in a hospital room 
previously occupied by an infected patient and contact with contaminated equipment. 9,13,14  
 
The contamination of hospital surfaces and equipment with biofilms is particularly concerning. 15 Biofilms 
are difficult to eliminate due to production of the extracellular matrix, which can reduce drug access to cells 
in the biofilm. Dormant (non-replicating) cells in the biofilm are also difficult to kill, since most antibiotics 
target processes involved in cellular division. Bacteria that express efflux pumps are capable of transporting 
antibacterials out of the cytoplasm, allowing for the persistence of cells. Some strains can also produce 
enzymes that degrade antibiotics (Fig. 1). 15,16 
 
A common organism that forms biofilms is Pseudomonas aeruginosa, an opportunistic pathogen that is 
capable of growing in nutrient-poor conditions and extreme temperatures. 15 P. aeruginosa strains can be 
mucoid or non-mucoid. Mucoid strains have a mutation in the negative-regulator mucA gene, which leads 
to overproduction of alginate, a capsule-like exopolysaccharide. As a component of the extracellular 
matrix, alginate protects P. aeruginosa from inflammatory responses and impedes antibiotic penetration. 17 
Nonmucoid P. aeruginosa strains produce little or no alginate but can synthesize alternative 
polysaccharides – Ps1 or Pel. 
The pel operon is conserved in 
all P. aeruginosa strains and 
produces a glucose-rich 
extracellular matrix. 18,19 The 
pel operon is regulated by the 
Wsp system, which consists of 
eight genes (Fig. 2). WspA is a 
chemotaxis receptor that 
catalyzes the methylation of 
downstream targets, which 
ultimately leads to the 
Figure 1. Biofilms are polymicrobial communities with multiple phenotypes. 
Production of extracellular polysaccharide (EPS) (green layer) hinders 
penetration of antibiotics into the biofilm. Antibacterial resistance strains (blue) 
may express drug efflux pumps or enzymes that degrade antibiotics. Dormant 
bacteria (orange) are difficult to kill since most antibiotics target machinery 
involved in cell division.  
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synthesis of cyclic di-GMP and stimulates 
biofilm formation. The methylesterase 
WspF inhibits cyclic di-GMP formation. 
17,20,21 P. aeruginosa strains with mutations 
in the wspF gene have upregulated pel 
genes and are hyper-biofilm formers. 21,22  
 
P. aeruginosa biofilms have been 
identified in hospital water pipes and on 
medical devices, such as bronchoscopes, 
central venous catheters, and dental 
syringes, and contribute to infection in 
patients. 9,15,23 Immunocompromised 
patients are especially susceptible to 
developing HAIs from biofilm-forming bacteria. P. aeruginosa is commonly found in the lungs of cystic 
fibrosis (CF) patients, where approximately 20 percent of CF patients are infected with P. aeruginosa at 
less than one year old. 24-26 CF patients have a mutation in the cystic fibrosis transmembrane receptor 
(CFTR), resulting in dehydrated surfaces in the lungs and decreased bicarbonate transport across cell 
membranes. The decreased secretion of bicarbonate affects the movement of mucus, leading to the 
production of dense aggregates of mucus in CF lungs. 25 The thick mucus promotes the colonization of 
inhaled bacteria and leads to chronic infection. 27 Bacteria that form biofilms in CF lungs are almost 
impossible to treat due to acquired resistance to antibiotics, contributing to a shorter lifespan (40 years) in 
patients even though treatment has improved in the past four decades. 24,28  
 
Beginning in 1983, the number of clinically approved antimicrobial agents has steadily dropped, 
contributing to growing concern over the treatment of biofilms and antibiotic resistant pathogens. 29 This 
rapid decrease in commercially available antimicrobial drugs in the past 30 years is due in part to 
deteriorating investment in antibiotic development. 30 Investors have become dissuaded from antibiotic 
Figure 2. The Wsp system in P. aeruginosa controls the 
synthesis of cyclic-di-GMP, which in turn, stimulates EPS 
production and other biofilm associated genes. WspF 
demethylates downstream targets of WspA and inhibits biofilm 
formation. 
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development due to short patent life (20 years), unclear regulatory guidelines, time-consuming clinical 
testing, and short consumer use of the drug. Instead, the pharmaceutical industry has shifted focus to 
chronic diseases, which have longer treatment periods than bacterial infections, and are becoming 
increasingly widespread in the U.S. Currently, less than a dozen large pharmaceutical companies focus on 
antibiotic development. 4  
  
In the past 15 years, only four novel antimicrobial classes and one new cephalosporin have been approved 
for clinical use: Streptogramins (quinupristin and dalfopristin), Oxazolidinones (linezolid), Lipopeptides 
(daptomycin), Lipoglycopepides (telavancin), and Ceftaroline. Resistance to these agents has already been 
observed in enterococci and staphylococci. 3 Reports of daptomycin-nonsusceptible (DNS) S. aureus and 
enterococci are particularly disconcerting as daptomycin is a last-resort drug used to treat multi-drug 
resistant (MDR) Gram-positive organisms and is commonly used to treat methicillin-resistant S. aureus 
(MRSA) strains that have reduced susceptibility to vancomycin. 3,31 
  
Even fewer antibacterial agents have been recently approved for clinical use against Gram-negative 
bacteria. Two new carbapenem antibiotics, ertapenem and doripenem, were introduced in 2001 and 2007, 
respectively. 29 Although doripenem has broad-spectrum activity against Gram-positive and Gram-negative 
bacteria, reduced susceptibility to doripenem among P. aeruginosa isolates has been reported. 32,33 
 
The presence of antibiotic resistant and biofilm-forming pathogens in a hospital setting is a threat to 
medical practices. 1,8,9,11,12,14,34 The development of novel antibacterial compounds is essential in the 
sterilization of medical equipment and treatment of bacterial infection caused by antibiotic resistant and 
biofilm forming pathogens.  
 
1.2 Amphiphile Background 
Amphiphiles, compounds with at least one hydrophobic tail and hydrophilic head group, are a promising 
option for antibacterial treatment. While most antibiotics act on specific biological targets within bacteria 
such as enzymes involved in transcription, cell wall synthesis, and translation, amphiphiles insert into 
	  	  
5	  
bacterial membranes. Compounds intercalated into the membrane can then disrupt the proton motive force, 
interfere with transmembrane proteins, or form openings in the membrane that lead to leakage of ions and 
cell death. 35-40 Repair of the cell membrane is a physiologically demanding task for bacteria and could 
impede development of resistance. 40  
 
In particular, cationic amphiphiles have promise as antibacterial therapeutics due to the differences in 
structure between bacterial and human cell membranes. 41 Bacterial cell membranes contain 20-25% 
phosphatidylglycerol and cardiolipin, which are negatively charged phospholipids, resulting in a net 
anionic charge (Fig. 3). 41 In contrast, eukaryotic cell membranes are primarily composed of zwitterionic  
(neutral) phospholipids, including phosphatidylcholine and phosphatidylethanolamine (Fig. 3). 42 Human 
plasma membranes also contain cholesterol, which impedes amphiphilic disruption of the membrane by 
increasing mechanical stability of the bilayer. 43,44 These differences in cell membrane structure between 
humans and bacteria account for the selectivity of some amphiphiles that disrupt bacterial membranes 
while leaving human cell membranes intact.   
 
Low-molecular weight amphiphiles in particular are promising candidates for antibacterial treatment due to 
their ability to permeate the outer membrane of Gram-negative bacteria. 36,45 The outer membrane is an 
additional lipid bilayer found in Gram-negative organisms that is covalently linked to the peptidoglycan 
Figure 3. Comparison of the cell membranes of Gram-positive bacteria, Gram-negative bacteria, and 
humans. Gram-positive organisms have a cell wall with a thick peptidoglycan layer. Gram-negative bacteria 
also have a peptidoglycan layer, but it is thinner and covered by an additional outer membrane. The outer 
membrane contains porins which allow the passage of low molecular weight molecules. The bacterial cell 
membrane contains negative phospholipids, resulting in a net anionic charge. In contrast, the human cell 
membrane is zwitterionic (neutral) and contains cholesterol, which increases stability of the human cell 
membrane. 
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layer and consists of anionic lipopolysaccharide, phospholipids, and proteins (Fig. 3). 45 The outer 
membrane acts as a barrier to antibiotics and contributes to the intrinsic resistance of Gram-negative 
organisms, restricting the size of transportable compounds to less than 700 daltons. 45 Gram-positive 
bacteria lack an outer membrane but have a thicker peptidoglycan layer that is relatively open to 
extracellular compounds and therefore, does not significantly contribute to antibiotic resistance (Fig. 3). 45 
 
Amphiphiles that demonstrate antibacterial activity against a broad spectrum of microorganisms have been 
utilized as antimicrobial agents in detergents, disinfectants, cosmetics, and other common household 
products. 46 The use of cationic amphiphiles as an antimicrobial agent was first reported in 1935, when 
benzalkonium chloride was used as pre-operative hand soap. 47 Since then, a large variety of novel 
amphiphiles have been synthesized in an effort to increase effectiveness and specificity. 35-38,48-63  
 
Amphiphiles make up a broad class of compounds and can differ dramatically in architecture. Conventional 
amphiphiles have one tail and one head group. True polycephalic amphiphiles are also single-tailed but 
have multiple head groups. 39 Gemini amphiphiles are double-tailed with two head groups attached by a 
linker. 63 Bola amphiphiles also contain two head groups but are attached by a longer hydrophobic chain 
(Fig. 4). 39 In addition to overall architecture, amphiphiles can vary in length and number of tails; 
composition and number of head groups; spacing between head groups; counter ion; and charge. 35-38,48-63 
These variations can affect micelle formation and antibacterial activity of amphiphiles.   
 
The effect of structure on critical micelle concentration  
Amphiphiles self-assemble into micellar aggregates at the critical micelle concentration (CMC) – exposing 
the aqueous head groups to the environment and clustering hydrophobic tails within the micelle. 64 At 
concentrations below the CMC, amphiphiles align at the air-water interface in equilibrium with dissolved 
monomers (Fig. 5). 64,65 Water molecules form a hydration shell around hydrophobic regions of the 
monomers. 66,67 At concentrations above the CMC, amphiphiles form aggregates in which hydrocarbon tails 
interact with each other, releasing water that was formerly associated with the tails. This results in a second 
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equilibrium between monomers and 
aggregates in solution (Fig. 5). 65,68 The 
micellization of amphiphiles allows for the 
release of water molecules, resulting in a net 
increase in entropy of the system. 65,67  
 
The CMC is affected by amphiphile 
structure. Increasing the length of a tail or 
number of tails decreases the solubility of 
the compound in aqueous solution and thus decreases the CMC. 61,69 The log(CMC) and tail length have a 
linear relationship that follows the equation: 
log(CMC) = A – Bn     (1) 
where A and B are constants and n is the number of carbons in each hydrocarbon tail. 70,71 The slope of the 
line, B, is also affected by the number of hydrophilic units. 72 Increasing the number of head groups 
increases the compound’s solubility and CMC. As a result, the CMC of polycephalic amphiphiles has a 
weaker dependence (smaller B) on tail length. 50,72 A recent study on dicarboxyl and tricarboxyl 
amphiphiles follows this trend. Linear plots of log(CMC) and tail length have a steeper slope for bicephalic 
amphiphiles than tricephalic amphiphiles.  50 
 
Studying the relationships between structure and 
micellization of amphiphiles can reveal information about 
a compound’s mechanism. At concentrations above the 
CMC, amphiphiles can act as a detergent in solution, 
solubilizing the membrane and forming phospholipid-
detergent aggregates.  49-51,54 
 
 
 
Figure 4. Structure of conventional, gemini, bola, and 
bicephalic amphiphiles. Amphiphiles contain at least one 
hydrophobic tail or linker (gray line) and at least one 
hydrophilic head group (black circles).  
Figure 5. As the concentration of amphiphiles 
in water reaches the CMC, micelles begin to 
form. Figure copied with permission from 
Marafino, J. N., "Colloidal and Biological 
Properties of Triscationic Amphiphiles with 
One or Two Tails" (2014). Masters Theses, 
2014 - Paper 7. 
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The effect of structure on antibacterial activity  
In addition to affecting thermodynamic properties, amphiphile structure also affects antibacterial activity. 
The antibacterial activity of a compound is often represented as the minimum inhibitory concentration 
(MIC) or minimum bactericidal concentration (MBC), where lower values indicate better antibacterial 
activity. Trends relating the head group composition and spacing; number of head groups; charge; and 
hydrophobicity to antimicrobial activity have been reported by multiple labs. 37,40,49-51,53-58,62,73  
 
The head group composition of amphiphiles varies and can affect antibacterial properties. When comparing 
the effectiveness of pyridinium head groups to that of trimethylammonium head groups in conventional, 
bicephalic, and tricephalic amphiphile series, pyridinium compounds have better activity (Table 1). 48 The 
pyridinium compounds killed multiple bacterial strains at lower concentrations and in less time than the 
trimethylammonium counterparts. 48 
 
In addition to head group composition, the spacing between cationic head groups in polycephalic 
amphiphiles can affect antibacterial activity. In a previous study conducted by our research group, 
amphiphiles that vary in the number of carbons (4-6) between trimethylammonium head groups were tested 
against Gram-negative and Gram-positive organisms. Amphiphiles with a 5-carbon spacer between the 
trimethylammoniums had the lowest MIC values. 39  
 
Several labs have reported the trend that antibacterial activity increases with increasing number of cationic 
head groups (Table 1). Haldar et al. synthesized two series of amphiphiles consisting of a single tail and 
one, two, or three cationic head groups attached to an ester. Both series follow the same trend where 
antibacterial activity increases with increasing head groups, with triple-headed amphiphiles having the  
greatest antibacterial activity against both Gram-positive and Gram-negative bacteria (Table 1). 48 Similar 
results were observed in previous studies by our research group investigating bicephalic and monocationic 
(conventional) amphiphiles. Overall, monocationic amphiphiles were ineffective against Gram-negative 
organisms whereas bicephalic compounds were more effective against multiple Gram-positive and Gram-
negative organisms (Table 1). 39  
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Other studies comparing the antibacterial activity of neutral amphiphiles to cationic amphiphiles further 
supports the trend that increasing cationic head groups leads to an increase in antibacterial activity (Table 
1). The bactericidal activity of quinolium and dipyridinium based compounds were compared to neutral 
counterparts. In both series of amphiphiles, the charged compounds had enhanced activity against 
planktonic bacteria and biofilms (Table 1). 36,38,40 The presence of a cationic charge likely increases the 
antibacterial activity of amphiphiles due to the interaction of cationic head group(s) with the anionic 
bacterial cell membrane and Gram-negative outer membrane.  
 
In contrast to the studies previously mentioned, changing the number of dimethylammonium head groups 
in novel quaternary ammonium compounds from two to three or four did not significantly affect 
antibacterial activity. 58 Similar results were reported for anionic dicarboxyl and tricarboxyl amphiphiles. 
The dicarboxyl compounds had better antibacterial activity than their tricarboxyl counterparts, with up to a 
50-fold decrease in MIC values.  51 This lack of head group effect on the activity of carboxyl and quaternary 
ammonium compounds may be explained by the differences in architecture. The architecture of the 
quaternary ammonium compounds are “gemini-like” with hydrophobic linkers between head groups, 
forming a chain-like shape. 58 The improved activity of the double-headed versus triple-headed carboxyl 
compounds may be explained by the effect of the balance between hydrophobicity and solubility. 51 In order 
to have antibacterial activity, a compound must be hydrophilic enough to dissolve in solution and 
hydrophobic enough to interact with the nonpolar lipid tails of the bacterial membrane. In this case, the 
triple-headed amphiphiles may have been too hydrophilic to interact with the lipid bilayer. 51 
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Table 1. Structure-activity trends from studies on novel amphiphiles. *indicates not all 
possible combinations of tail lengths synthesized.  
Amphiphile(s) Structure Trend(s) Reference
!Pyridinium head groups 
have better activity than 
trimethylammonium       
!Increase in # of head 
groups led to increased 
activity
[48] Haldar, et 
al. J. Med. 
Chem. 2005, 
48, 3823-3831.
!Five carbon spacer has 
best activity                              
!Increase in # of head 
groups led to increased 
activity
!Moderate tail length has 
best activity (12-16 
carbons)
[39] Ladow, et 
al. Eur. J. Med. 
Chem. 2011, 
46, 4219-4226.
!Cationic amphiphiles have 
better activity than neutral 
counterpart                      
!Moderate tail length has 
best activity (12 carbons)
[38] Goswami, 
et al. Journal 
of Materials 
Chemistry B 
2013, 1, 2612-
2623.
!Cationic amphiphiles have 
better activity than neutral 
counterpart                       
!Moderate tail length has 
best activity (12 carbons)
[40] Vudumula, 
et al.RSC 
Advances. 
2012, 2, 3864-
3871.
!Moderate tail length has 
best activity (16-20 
carbons)
[54] Sugandhi, 
et al. J. Med. 
Chem. 2007, 
50, 1645-1650.
!Moderate tail length has 
best activity (22 carbons 
total)
[56] Black, et 
al. Bioorganic 
Med. Chem 
Let. 2014, 24, 
99-102.
!Moderate tail length has 
best activity (22 carbons 
total) 
[59] Grenier, et 
al. Bioorganic 
Med. Chem 
Let. 2012, 22, 
4055-4058
R= CnH2n+1 
n=8, 12 
X+ = N+Me3 or pyridinium 
  
 
  
 
R= CnH2n+1 
n=8, 12 
X+= triethanolamine 
R= CnH2n+1 
n=14, 16, 18, 20, 22 
R1= CnH2n+1 
n=8, 10, 12, 14, 16, 18* 
R2= CmH2m+1 
m= 8, 10, 11, 13, 12, 14, 16, 18* 
R1= CnH2n+1 
n=1, 2, 4, 6, 8, 10, 11, 12, 14, 16, 18, 20* 
R2= CmH2m+1 
m=8, 10, 11, 12, 14, 16, 18, 20* 
n=10, 12, 14, 
16, 18 
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The hydrophobicity of a compound, determined by the number of polar head groups versus the number and 
length of nonpolar tails, influences antibacterial activity by affecting the ability of a compound to 
incorporate into the bacterial membrane. Long hydrophobic tails readily incorporate into the nonpolar lipid 
bilayer. However, unless balanced by a charged substituent, these compounds are less soluble and can form 
aggregates in solution at low concentrations, rendering some amphiphiles useless as antibacterials. 57 
 
Some amphiphiles demonstrate chain length specificity within a particular series, meaning a compound has 
an optimal tail length for the greatest antibacterial activity. 35,38-40,53,56,59 Typically, the MIC or MBC of a 
compound will decrease with increasing tail length until an optimal length is reached. After this point, the 
MIC or MBC increases. The optimal tail length of amphiphiles within a homologous series varies based on 
the number of polar head groups and overall architecture. When investigating the effect of tail length on 
activity of conventional amphiphiles (one head and one tail), 12 carbon derivatives have the greatest 
antibacterial activity against multiple bacterial strains (Table 1). 38,40  
 
Bicephalic amphiphiles follow a similar pattern – the reported optimal tail lengths range from 12-16 
carbons, depending on the Gram-nature of the target bacteria (Table 1). 39 Addition of a third head group 
extends the optimal tail length to 16-20 carbon tails (Table 1). 49,54 Amphiphiles with non-conventional 
architecture are also antibacterial at an optimal tail length. Gemini amphiphiles (double-head, two tails) 
have an optimal tail length of 11 or 12 carbons, with a total carbon count of 22-24 carbons (Table 1). 56,59 
  
Relationship between critical micelle concentration and minimum inhibitory concentration 
As expected, multiple studies on antibacterial amphiphiles have reported MIC values lower than the CMC. 
49-51,54 These results suggest that aggregation is not necessary for amphiphiles to exhibit antibacterial 
activity. Rather, these antibacterial amphiphiles likely interact with the bacterial cell membranes as 
monomers dissolved in solution. 49-51,54 
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Biofilm disrupting amphiphiles 
Amphiphiles have potential as novel antibacterial treatment for biofilms. Hospital surfaces and medical 
devices contaminated with biofilms are difficult to disinfect and contribute to HAIs. 9,12,15 Biofilms can also 
cause bacterial infection in immunocompromised patients, such as in the lungs of CF patients, leading to 
chronic infection and inflammation. 24,25 Low molecular weight amphiphiles may be able to penetrate the 
extracellular polysaccharide matrix and interact with bacterial cells. 36 Several in vitro studies have 
identified amphiphiles that disrupt P. aeruginosa and Gram-positive biofilms. Quinolinium and 
dipyridinium amphiphiles eradicated P. aeruginosa and S. aureus biofilms at concentrations ranging from 
30-200 µM. 36,62 Novel bisamines and trisamines disrupted S. aureus biofilms at concentrations as low as 50 
µM. 73 
 
Synergistic amphiphiles  
Some compounds act synergistically when combined with another antibacterial agent. The use of 
synergistic combinations of antibiotics has proven beneficial in the treatment of bacteremia, pneumonia, 
septic shock, and skin infections. 36,38,62,74-80 Several hospital studies reported that the use of two antibiotics 
compared to one contributed to lower mortality rates in patients, including patients infected with antibiotic 
resistant pathogens. 76-81 Utilization of combinations of antibiotics has also been reported to help prevent the 
emergence of antibiotic resistance in clinical isolates. 82,83  
 
In vitro and in vivo studies demonstrating that cationic amphiphiles act synergistically with antibiotics, 
alcohol, and other antimicrobials suggest combination therapy involving the use of amphiphiles has 
promise in the treatment of bacterial infection and prevention of the transmission of bacteria. Quinolinium- 
and dipyridinium-based synthetic amphiphiles interacted synergistically with erythromycin and 
tobryamycin against multiple Gram-negative organisms and with polymyxin against S. aureus. 38,62 
Furthermore, synergistic combinations of those amphiphiles with tobramycin disrupted in vitro P. 
aeruginosa biofilms, with tobramycin concentrations as low as 0.16 µg/ml. 36,62 Electron microscopy 
analysis of P. aeruginosa biofilms treated with tobramycin and the dipyridinium compound indicated the 
combination disrupted cell-cell adhesion and reduced the amount of extracellular polysaccharide. 36  
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Combinations of cationic amphiphiles with another antimicrobial agent have been shown to increase the 
efficacy of alcohol hand rubs and soaps. 84-86 One study compared the effectiveness of soaps containing 
triclosan, an antibacterial and antifungal agent, to soaps containing a combination of benzethonium chloride 
and triclosan. The soap with the combination had better antibacterial activity in a volunteer method and 
pig-skin model. In addition, the use of the triclosan-benzethonium chloride combination reduced the risk of 
antibiotic resistance development.  85 
 
Early in vitro studies with amphiphiles can identify promising drug leads that are synergistic with other 
antibacterial agents, capable of disrupting biofilm, and/or show activity against a broad spectrum of 
pathogens. The safety and efficacy of lead compounds must then be determined following the drug 
development process.  
 
1.3 Drug Development  
The development of drugs follows the same sequence of events and takes 12-15 years of R&D before the 
drug is approved by the FDA and can cost up to two billion dollars. 4 The first phase of drug R&D is the 
identification of a target for treatment of the disease of interest – usually a protein or specific structure (Fig. 
6). An assay must then be developed and used to screen for compounds that are effective at targeting the 
structure. 4,87 
 
After identifying drug leads with activity for the target, the specificity and toxicity of the drug candidates 
must be investigated (Fig. 6). The cytotoxicity of drugs can be tested in vitro with animal or human cell 
Figure 6. Drug development process. The drug development process takes 12-15 years and involves 
proving the efficacy and safety of a drug in preclinical and clinical studies.   
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cultures. 4,87 Early safety studies on amphiphiles investigated the toxicity with human or sheep red blood 
cells and epithelial cell lines. 36-38,40,49,51,62 The concentrations utilized to assess the cytotoxicity of a 
compound are EC10 or EC50, the concentration of amphiphile that results in 10% or 50% cell death. The 
therapeutic range of an amphiphile can then be calculated by dividing the EC10 or EC50 by the MIC. 35-
38,49,51,62 Although the therapeutic range is widely used as a measurement of preclinical and clinical toxicity, 
no regulations on the analysis of the therapeutic range exist. 88 A larger therapeutic range indicates higher 
specificity of an amphiphile for the bacterial target. 
 
After demonstrating the compounds are nontoxic to human cells, the researchers must file an 
Investigational New Drug application with the FDA before proceeding with clinical trials. Clinical trials 
consist of three (or four) phases (Fig. 6). The first phase tests the compound in a small group of healthy 
volunteers to determine if the compound is safe in humans. Phase II involves testing the efficacy of the 
drug in diseased individuals and examines short-term effects. The optimal drug dose is also determined in 
phase II. Phase III assesses the overall safety and risk-benefit ratio of the drug in a large sample of patients. 
After demonstrating the compound is safe in humans and has an acceptable risk-benefit ratio, a New Drug 
Application is submitted to the FDA. If the application is approved, the drug can be marketed and made 
available for use. In some cases, the FDA may also require a fourth phase study in order to examine long-
term safety of the drug. 4,87  
 
1.4 Amphiphiles in the current study 
Three novel series of triple-headed amphiphiles were synthesized by the Caran Lab (James Madison 
University Department of Chemistry and Biochemistry) and structure-activity relationships were 
investigated (Fig. 7). All three series of amphiphiles consist of three cationic head groups attached to a 
mesitylene core (M). For the M-P and M-1 series, two of the head groups are dimethylalkylammonium 
groups with linear, symmetrical hydrocarbon tails consisting of 8-16 carbons. The third head group is either 
pyridinium (M-P) or trimethylammonium (M-1) (Fig. 7a,b) For the M-1,1 series, one of the head groups is 
dimethylalkylammonium with a single, linear hydrocarbon tail consisting of 8-22 carbons attached. The 
other two head groups are trimethylammonium groups (M-1,1) (Fig. 7c).  
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Once synthesized, the effect of amphiphile structure on the colloidal and antibacterial properties was 
investigated. The modification of head group composition, number of tails, and length of tail(s), led to the 
identification of lead compounds that have antibacterial activity against a broad spectrum of bacteria. 
Antibacterial compounds were then tested in combination to identify synergistic combinations, and the 
toxicity of antibacterial compounds was determined in hemolysis assays.   
 
 
 	  	  
  
Figure 7. Structure of amphiphiles. (a) M-P series (b) M-1 series (c) M-1,1 series; where M refers to 
the Mesitylene core, P represents the pyridinium head group; and n represents the number of 
hydrocarbons in the tail; a number indicates the number of carbon atoms in the alkyl group of a 
dimethylalkyl ammonium (e.g., 1 = trimethylammonium; 8 = octyldimethylammonium).  
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Chapter 2: Colloidal and antibacterial properties of novel triple-headed, double-tailed amphiphiles: 
exploring structure-activity relationships and synergistic mixtures 
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Abstract: 
Two novel series of tris-cationic, tripled-headed, double-tailed amphiphiles were synthesized and the 
effects of tail length and head group composition on the critical aggregation concentration (CAC), 
thermodynamic parameters, and minimum inhibitory concentration (MIC) against six bacterial strains were 
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investigated. Synergistic antibacterial combinations of these amphiphiles were also identified. Amphiphiles 
in this study are composed of a benzene core with three benzylic ammonium bromide groups, two of which 
have alkyl chains, each 8 to 16 carbons in length. The third head group is a trimethylammonium or 
pyridinium. Log of critical aggregation concentration (CAC) and heat of aggregation (∆Hagg) were both 
inversely proportional to the length of the linear hydrocarbon chains. Antibacterial activity increases with 
tail length until an optimal tail length of 12 carbons per chain, above which, activity decreased. The 
derivatives with two 12 carbon chains had the best antibacterial activity, killing all tested strains at 
concentrations of 1-2 µM for Gram-positive and 4-16 µM for Gram-negative bacteria. The identity of the 
third head group (trimethylammonium or pyridinium) had minimal effect on colloidal and antibacterial 
activity. The antibacterial activity of several binary combinations of amphiphiles from this study was 
higher than activity of individual amphiphiles, indicating that these combinations are synergistic. These 
amphiphiles show promise as novel antibacterial agents that could be used in a variety of applications.  
 
 
2.1 Introduction 	  
Over the past few decades, the overuse of antibiotics has resulted in an increase in antibiotic-resistant 
bacteria. 89-93 In addition, the production of novel antimicrobials continues to decrease, primarily due to low 
financial return. 4,93 This combination of circumstances has contributed to the increasing prevalence of 
antimicrobial-resistant infections (ARIs), especially in the hospital setting. ARIs have contributed to tens of 
thousands of deaths per year in the European Union and United States alone. 1,94 Hospitals and nursing 
homes are particularly prone to harboring antimicrobial-resistant organisms due to the frequent use of 
antimicrobial agents and an influx of infected, and frequently, immunocompromised patients. 95 Limiting 
the transmission of bacteria from contaminated equipment and individuals to a susceptible population is 
critical to reducing the risk of hospital acquired infections by antibiotic resistant organisms. 95,96 The 
development of effective novel antibacterials could be of benefit in the healthcare setting by decreasing the 
cost associated with treating infected patients, and ultimately, decreasing mortality due to these types of 
infections. 97 
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The use of cationic amphiphiles as antimicrobials was first reported in 1935. 47 Amphiphiles continue to be 
utilized as antimicrobial agents in detergents, disinfectants, cosmetics, and other common household 
products. 46 A large variety of novel amphiphiles has been synthesized in an effort to increase effectiveness 
and specificity. 39,48,98-106  
  
Amphiphile structure, including size and relative number of hydrophobic tails and hydrophilic head groups, 
governs colloidal characteristics including the critical aggregation concentration (CAC) and 
thermodynamic properties. 65 At concentrations below the CAC, amphiphiles tend to align at the air-water 
interface in equilibrium with dissolved monomers in solution. 65,107 At concentrations above the CAC, 
amphiphiles form aggregates in which hydrocarbon tails interact with each other releasing water that was 
formerly associated with the tails, resulting in a second equilibrium between monomers and aggregates in 
solution. 65,68 An increase in entropy typically associated with aggregate formation is generally attributed in 
large part to the release of water molecules surrounding hydrophobic units to the bulk water that 
accompanies this process. 65 Increasing amphiphile hydrophobicity (for example by increasing the length or 
number of tails) decreases water solubility, thus decreasing CAC. In contrast, additional head groups can 
increase amphiphile solubility, typically resulting in a higher CAC. 61,69,108,109 
 
Amphiphile structure also affects antimicrobial effectiveness. A trend reported by multiple studies is the 
relationship between amphiphile tail length and the minimum inhibitory concentration (MIC), the lowest 
concentration at which an antimicrobial is able to inhibit microbial growth. Typically, as tail length 
increases the MIC decreases until an optimal tail length is reached. The MIC then increases for amphiphiles 
with tail lengths exceeding this optimal length. 39,98-104 Variations in spacing between head groups can also 
impact the MIC. For example, studies conducted by our labs show that amphiphiles with a 5-carbon spacer 
between two cationic head groups are the most biologically active. 39 The amphiphiles in the current study 
also have a 5-carbon spacer between cationic groups.  
 
Some mixtures of two or more amphiphiles exhibit synergy – the inhibition of bacteria at lower 
concentrations than when each amphiphile is used separately. 110 By decreasing the required concentration 
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of compounds, combination therapy reduces the potential for, or degree of, adverse side effects and 
increases the effectiveness of antibacterial agents. The improved efficacy of synergistic combinations has 
contributed to the improvement of hand disinfectants and effective treatment for patients with ARIs. 
76,80,85,111  
 
In this report, the synthesis and colloidal, antibacterial, and synergistic characteristics for two novel series 
of triple-headed, double-tailed amphiphiles are reported (Fig. 8). Amphiphiles in this study consist of three 
cationic head groups connected to a mesitylene (M) core. Two of the head groups are 
dimethylalkylammonium groups with linear hydrocarbon tails from 8 to 16 carbons in length. The third 
head group is either pyridinium (M-P series) or trimethylammonium (M-1 series).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Structures of triple-headed, double-tailed 
amphiphiles in this study. Compounds are named as 
follows: M-X,n,n where M refers to the Mesitylene 
core, and X and n represent the attached groups: P 
indicates a pyridinium; a number indicates the number 
of carbon atoms in the alkyl group of a dimethylalkyl 
ammonium (e.g., 1 = trimethylammonium; 8 = 
octyldimethylammonium). 	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2.2 Results & Discussion 
 
Synthesis  
Each of the amphiphiles in this study was prepared by two subsequent Menshutkin reactions (Scheme 1). 
To prepare the M-P series (1-5), 1,3,5-trisbromomethylbenezene was reacted with a slight excess of 
pyridine resulting in intermediate 11 (77% yield). Selective reaction at just one of the three equivalent 
benzylic positions was aided by the decreased solubility of the desired product, which precipitates from the  
reaction mixture upon formation. Filtration and washing with acetone provides compound 11 in sufficient 
purity for the next synthetic step. Substitution of the two remaining benzylic bromides on 11 was 
accomplished using excess dimethylalkylamine (NMe2(CH2)n-1CH3, where n = 8, 10, 12, 14 or 16) in 
ethanol at reflux producing the M-P series of amphiphilic products 1-5 (63 – 92% yield). 
 
To prepare the M-1 series (6-10), 1,3,5 trisbromomethylbenezene was reacted with a slight excess of 
trimethylamine resulting in intermediate 12 (37% yield). This reaction produces primarily 12, along with a 
highly insoluble biscationic byproduct (a result of two benzylic bromides being substituted with 
trimethylamine), which can be effectively removed by an extraction protocol as detailed in the 
Scheme 1. Synthesis of triple-headed, double-tailed amphiphiles. 	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experimental section. Substitution of the two remaining benzylic bromides on 12 was accomplished using 
excess dimethylalkylamine (NMe2(CH2)n-1CH3, where n = 8, 10, 12, 14, 16) in ethanol at reflux producing 
the M-1 series of amphiphilic products 6-10 (20 – 75% yield). 
 
Critical aggregation concentration and heat of aggregate formation 
Isothermal titration calorimetry (ITC) was used to determine the critical aggregation concentration (CAC) 
and the thermodynamic parameters associated with aggregate formation for each amphiphile (Table 2). 
Briefly, the Nano ITC was used 
to measure the heat change 
associated with the 
deaggregation of amphiphiles via 
power compensation. 112-115 A 
concentrated aqueous solution of 
amphiphile (>>CAC) was 
titrated into a thermally 
controlled sample cell, initially 
containing pure water, in a series 
of discrete injections. Typical 
ITC results can be divided into 
three ranges associated with the 
concentration of amphiphile in 
the sample cell below, at, and 
above the CAC, as seen for  
compound 9 (M-1,14,14, 9). 
During initial injections (Range I), measured heat changes are due to both the dilution of aggregates and 
deaggregation. This can be observed in the first 10 injections, where aggregates absorbed heat and 
disassociated into dissolved monomers.1 The  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Typically the 1st injection is ignored.  
Figure 9. Isothermal titration calorimetry was used to determine the 
critical aggregation concentration (CAC) and ∆Hagg. a) The heat rate 
associated with each injection versus time for 9 (M-1,14,14). b) 
Integration of the heat per injection normalized by the number of moles 
of each injection versus the increasing concentration of amphiphile in the 
well. Inset: CAC is determined by calculating the first derivative the heat 
curve.	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heat change produced by each injection was approximately constant in this range. In Range II, injected 
aggregates don’t fully dissociate, reducing the total absorbed heat for each subsequent injection. At 
concentrations well above the CAC (Range III), absorbed heat is attributed only to the dilution of 
aggregates and is approximately constant. The CAC was determined by the inflection point in Range II, as 
measured by the minimum value in the plot of CAC versus the first derivative of the heat (Fig. 9, inset). 
Analogous results were recorded for compounds 2-5 and 7-10, the results of which are presented in Table 
2. CAC and thermodynamic data were not determined for the amphiphiles with the shortest tails [1 (M-
P,8,8) and 6 (M-1,8,8)] because the heat evolved during injection was above the threshold of the 
instrument. 
 
Both series of compounds exhibit a decrease in CAC as tail length increases (Table 2). CAC values for the 
M-P and M-1 series are approximately equivalent for each tail length, following a linear plot of log(CAC) 
versus tail length (Fig. 10a) according to the equation: 
 
log(CAC) = A – Bn     (1) 
 
where A and B are constants and n is the number of carbons in each hydrocarbon tail. 61,70,116 The 
dependence of CAC on tail length is the same for each series (B = 0.31).  
M-P M-1 Tail Length (n for M-X,n,n) 
CAC (mM) ∆Hagg (kJ/mol) ∆Gagg (kJ/mol) -T∆Sagg (kJ/mol) 
M-P M-1 M-P M-1 M-P M-1 M-P M-1 
2 7 10,10 14 12 -11 -15 -21 -22 -10 -6.6 
3 8 12,12 2.4 2.5 -23 -26 -26 -26 -3.1 -0.082 
4 9 14,14 0.60 0.61 -34 -37 -29 -29 4.9 8.0 
5 10 16,16 0.18 0.16 -42 -55 -33 -33 9.2 22 
Table 2. Critical aggregation concentration (CAC) and thermodynamic parameters at 37 °C for the M-P and M-1 
series. 
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The difference between the average 
heat of injections in Range I, 
representing the total heat due to the 
dilution of aggregates and 
deaggregation, and the average heat of 
injections in Range III, representing the 
heat due solely to the dilution of 
aggregates, gives the heat of 
deaggregation, ∆Hdeagg. The ∆Hdeagg for 
compound 9 (M-1,14,14) is 37 kJ/mol, 
corresponding to a heat of aggregate 
formation, ∆Hagg, of -37 kJ/mol (∆Hagg 
= -∆Hdeagg). The negative ∆Hagg values 
indicate that aggregation is an 
exothermic process for all of the 
amphiphiles in the study (Table 2). This is attributed to the release of heat accompanying aggregate 
formation from additional hydrogen bonding of water molecules joining the bulk, and from hydrocarbon 
tail interactions in the newly formed aggregate. Furthermore, ∆Hagg becomes more negative as tail length 
increases for both series of amphiphiles, following a linear trend (Fig. 10b) according to the equation: 
 
∆Hagg = C – Dn      (2) 
 
where C and D are constants and n is the number of carbons in each hydrocarbon tail. 61,70,116 The 
dependence of ∆Hagg on tail length is similar for each series (D = -5.1 for the M-P series; D = -5.8 for the 
M-1 series). The inverse relationship between ∆Hagg and amphiphile tail length is consistent with a larger 
amount of water released per molecule of amphiphile, as well as greater van der Waals interactions 
between the longer tails.  
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Figure 10. Plots of log(CAC) (a) and ∆Hagg (b) versus tail length at 
37 °C for the M-P (¢) and M-1 (n) series. 
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The ∆Gagg can be approximated for the aggregation of nonionic amphiphiles by the equation 
 
∆Gagg = RT ln (CAC/55.5)     (3) 
 
where the CAC represents an equilibrium between monomeric and aggregated amphiphiles. 71,117 The CAC 
is expressed as a molar fraction [molar units divided by the molar concentration of water (55.5 mol/L)]. 
This equation changes for ionic amphiphiles due to the presence of counterions and the degree of ionization 
at the aggregate surface. Thus the equation is modified for an ionic amphiphile as 71,117 
 
∆Gagg = RT [1+(m/n)] ln (CAC/55.5)   (4) 
 
where m is the concentration of counterions that associate with a aggregate and n is the number of 
monomers that associate to form an aggregate. 71,117 Since this study did not include determination of the 
degree of ionization or aggregate aggregation, ∆Gagg was approximated using equation (3), as has been 
done by others. 69,114,115 The ∆Gagg for all compounds in the study is negative and becomes more negative as 
tail length increases (Table 2). Thus the increase in chain length within a series of amphiphiles is consistent 
with the increased propensity to spontaneously form aggregates.  
 
The entropy of aggregation (∆Sagg) is dictated by a combination of entropic factors that favor or disfavor 
aggregate formation and can be approximated using the Gibbs-Helmholtz equation: 
 
∆Gagg = ∆Hagg - T∆Sagg     (5) 
 
To aid the reader, the entropic contribution to ∆Gagg, is presented as the negative of T∆Sagg (Table 2). In 
both series, the -T∆Sagg term is negative for amphiphiles with chain lengths of up to 12 carbons [2 (M-
P,10,10), 3 (M-P,12,12), 7 (M-1,10,10), and 8 (M-1,12,12)]. This suggests that the entropy gained from the 
release of water from hydrophobic sections is greater than the decrease in entropy of amphiphiles due to the 
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formation of aggregates. Thus the entropic factor, for amphiphiles with shorter chain lengths, contributes to 
the spontaneous formation (negative ∆Gagg) of aggregates.  
 
The -T∆Sagg term is positive for double tailed amphiphiles with tail lengths exceeding 12 carbons [4 (M-
P,14,14), 5 (M-P,16,16), 9 (M-1,14,14), and 10 (M-1,16,16)]. This suggests that the entropy gained from 
the release of water from hydrophobic units is smaller than the decrease in entropy of amphiphiles due to 
the formation of aggregates. Thus amphiphiles with longer chains entropically disfavor formation of 
aggregates making aggregate formation of these derivatives solely an enthalpy-driven process. This 
decrease in entropy may be explained by considering the effect of an amphiphile’s cone angle on aggregate 
size. 70 As tail length increases in a series of analogous amphiphiles, the cone angle decreases resulting in a 
higher aggregation number per aggregate. Formation of larger aggregates results in a larger decrease in 
entropy upon aggregate formation due to the greater number of amphiphiles per aggregate. 
 
Minimum inhibitory concentration 
The MIC values of all compounds from both series were determined for four Gram-positive 
(Staphylococcus aureus, Enterococcus faecalis, Streptococcus agalactiae, and Bacillus cereus) and two 
Gram-negative (Escherichia coli and Pseudomonas aeruginosa) strains (Table 3). For both series, the MIC 
decreases with tail length until an optimal tail length of 12 carbons per chain, above which the MIC 
increases (Fig. 11). The derivatives with two 12-carbon chains, compounds 3 (M-P,12,12) and 8 (M-
1,12,12), have the lowest MIC values against each strain with values ranging from 1-2 µM for Gram-
positive bacteria and 4-16 µM for Gram-negative bacteria. This trend is indicative of the relationship 
between solubility and bioactivity and is consistent with previous studies on other amphiphile series. 39,98,102 
Higher MIC values against Gram-negative strains may be due to their outer membrane, which is not present 
in Gram-positive bacteria. 
 
Many antibacterial agents are ineffective against P. aeruginosa due to its semipermeable outer membrane 
and production of efflux pumps and β-lactamases. 27 The contamination of medical equipment with P. 
aeruginosa biofilms contributes to hospital-acquired infections, particularly caused by antibiotic-resistant  
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strains. 9-12,34 While other antibacterial agents fail to inhibit P. aeruginosa, two amphiphiles in this study [3 
(M-P,12,12) and 8 (M-1,12,12)] kill this organism at relatively low concentrations, which may prove useful 
in a healthcare setting. Notably, MIC values of compounds 3 (M-P,12,12) and 8 (M-1,12,12) against P. 
aeruginosa (8 µM and 16 µM, respectively) are comparable to those of tobramycin (6.4 µM), commonly 
used to treat infection in cystic fibrosis patients, and cefepime (12.5 µM), an antispeduomonal 
cephalosporin. 118,119 
  
MIC values between respective M-P and M-1 tail lengths were generally similar, indicating that replacing 
the trimethylammonium head group with a pyridinium did not significantly affect bioactivity. A notable 
exception is observed between the two derivatives with 16-carbon chains, where the trimethylammonium 
derivative (10, M-1,16,16) was more effective than the pyridinium derivative (5, M-P,16,16) for all strains 
except P. aeruginosa. For all tested compounds, the MBC was the same concentration or a two-fold 
concentration higher than the MIC, indicating the amphiphiles are bactericidal, consistent with previous 
studies on other multiheaded amphiphiles. 39,120 
 
With only a few exceptions, MIC values are significantly below CAC values, demonstrating that 
amphiphile aggregation is not required to kill bacteria. 102 At concentrations near or above the CAC the 
amphiphile may act as a detergent, solubilizing the cell membrane – a mechanism of action that could be 
detrimental to prokaryotic cells. 100,102 Amphiphiles at sub-CAC levels are potent antibacterials at 
concentrations where detergent effects are not observed. It is recognized CAC values reported here 
(measured in pure water) may differ to some degree from the CAC values in the medium used for MIC 
studies. 
Table 3. MIC values (µM) for M-P and M-1 amphiphiles. G+ = Gram-positive, G- = Gram-negative. 
 
M-P M-1 Tail length (n for M-X,n,n) 
B. cereus 
(G+) 
E. faecalis 
(G+) 
S. agalactiae 
(G+)  
S. aureus 
(G+) 
E. coli 
(G-) 
P. aeruginosa 
(G-)  
M-P M-1 M-P M-1 M-P M-1 M-P M-1 M-P M-1 M-P M-1 
1 6 8,8 >250 >250  >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 
2 7 10,10 8 8 8 8 8 4 2 16 16 125 63 >250 
3 8 12,12 2 2 2 2 1 2 2 2 4 4-8 8 16 
4 9 14,14 8 4 4 4 4 2-4 4 4-8 16 8 63 125 
5 10 16,16 >250 16 >250 32 >250 8 >250 16 >250 63 >250 >250 
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Synergistic combinations 
In addition to determining the antibacterial activity of individual amphiphiles, combination studies were 
performed in order to determine if binary mixtures of amphiphiles demonstrate synergy in killing 
representative Gram-positive (S. aureus) and Gram-negative (E. coli) organisms (Fig. 12). A combination 
is considered synergistic if a mixture of amphiphiles has greater antimicrobial activity than simply an 
additive effect. The fractional inhibitory concentration (FIC) was used to indicate whether two chemicals 
Figure 11. Plot of log(MIC) and tail length for the M-P and M-1 series. (M-P series = ¢; M-1 series = 
n). # = MIC > 250 µM. G+ = Gram-positive; G- = Gram-negative. 
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were synergistic (FIC<0.5), indifferent (FIC 0.5-4.0), or antagonistic (FIC>4.0). 110 Two amphiphile 
combinations are synergistic against S. aureus: combinations of compounds 3 and 4 (FIC=0.31) and 
compounds 3 and 10 (FIC=0.38). In addition, one combination is synergistic against E. coli: compound 3 
and 9 (FIC=0.38). All three synergistic combinations contain compound 3 (M-P,12,12). The use of 
synergistic antibacterial combinations could be beneficial in a health-care setting, where frequent 
antimicrobial use has contributed to the presence of antibiotic-resistant organisms. 74-76,80,82,85,121  
 
2.3 Conclusions  
 
Two novel series of amphiphiles were synthesized and structure-activity relationships were investigated. 
Log (CAC) and ∆Hagg each decrease linearly with increasing tail length for both series. For most of the 
amphiphiles in this study, the MIC is significantly below the CAC, indicating amphiphile aggregation is not 
necessary for antibacterial activity. MIC values also indicated an optimal tail length of 12 carbons for each 
series as compounds 3 and 8 (M-P,12,12 and M-1,12,12) have the lowest MIC against all strains tested. 
Furthermore, three binary combinations of amphiphiles have been identified that exhibit synergistic 
Figure 12. Synergy studies for M-P and M-1 amphiphiles tested against E. coli 
and S. aureus. The FIC value for each combination is given. Shaded blocks 
indicate synergistic combinations (FIC <0.5). Numbers below the diagonal 
represent FIC values against S. aureus. Numbers above the diagonal represent 
FIC values against E. coli.  	  
	  	  
29	  
relationships. These amphiphiles could prove useful in the medical field especially when treating or 
preventing infection with antibiotic-resistant organisms.  
 
2.4 Methods and Materials 
 
Synthesis 
Synthesis of 11 
1,3,5-tribromomethylbenezene (1.0 g, 2.8 mmol, Sigma-Aldrich) was dissolved in acetone (200 mL) at 
room temperature in a round bottom flask. The solution was equipped with a stir-bar and attached to an 
addition funnel. Pyridine (0.45 mL, 5.6 mmol, Sigma-Aldrich) was dissolved in acetone (100 mL) and 
added drop-wise to the stirring solution of 1,3,5-tribromethylbenzene at room temperature and allowed to 
react overnight. A white precipitate formed. The crude reaction mixture was vacuum filtered, washed with 
acetone, and dried under vacuum yielding 943 mg (77%) of a tan solid, 11. See Supporting Information for 
analytical data.  
 
Synthesis of 12 
1,3,5-tribromomethylbenezene (2.01 g, 5.6 mmol) was dissolved in acetone (400 mL)  at room temperature 
in a round bottom flask. The solution was cooled on an ice bath for 30 minutes, equipped with a stir-bar, 
and attached to an addition funnel. An ethanolic trimethylamine solution (1.6 mL, 6.7 mmol, ACROS) was 
diluted with acetone (200 mL) and cooled on an ice bath for 30 minutes. The trimethylamine solution was 
added drop-wise to the stirring solution of 1,3,5-tribromethylbenzene. The reaction was run overnight, and 
allowed to warm slowly to room temperature. A white precipitate containing a mixture of 12 and a 
biscationic side product formed. The crude reaction mixture was briefly heated to 50°C and vacuum 
filtered. The mother liquor (which contained a mixture of 12 and unreacted starting material) was 
transfered to a clean RBF and the solvent was removed by rotary evaporation. The resulting solid was 
resuspended in room temperature acetone for 30 minutes, vacuum filtered, and dried under vacuum 
yielding 12 (white solid). The solid filtered from the crude reaction mixture was resuspended in a solution 
of acetone and ethanol (100:3), heated to 60 °C, stirred for at least 30 minutes, and vacuum filtered. The 
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filtrate was transferred to a clean flask and the solvent was removed by rotary evaporation yielding 
additional 20 (white solid, total yield = 860 mg, 37%). See Supporting Information for analytical data. 
 
Synthesis of 1-10: General Protocol A 
Compound 11 or 12 was added to a two-neck round bottom flask and dissolved in ethanol. The flask was 
equipped with a stir bar and attached to a water-cooled condenser. Excess dimethylalkylamine 
(NMe2(CH2)n-1CH3,where n = 8, 10, 12, 14 or 16) was added slowly to the flask via syringe. The reaction 
was heated to reflux and allowed react overnight. Volatile materials were removed under a flow of N2 (g). 
The resulting crude solid was resuspended in acetone to dissolve any residual dimethyalkylamine and 
vacuum filtered to yield the solid amphiphile product (1-10). Details for each product and analytical data 
are provided in the Supporting Information.  	  
Isothermal Titration Calorimetry 
CAC and ∆Hagg were determined using a Nano-ITC (TA-Instruments). Prior to each experiment the sample 
cell was washed with dH2O (300 mL), ethanol (100 mL), dH2O (300 mL) and nanopure water (200 mL). 
Next, 950 µL of nanopure water was added to the sample cell. A concentrated aqueous solution (>>CAC) 
of amphiphile was prepared and equilibrated at 37 °C. A 250 µL syringe was filled with the aqueous 
solution, and loaded into the Nano ITC. Multiple single injections in aliquots of 5 µL were injected into the 
sample cell with time intervals varying from 300s to 1400s. Samples were continuously stirred (300 rpm) 
throughout the titration. The Nano-Analyze program (TA-Instruments) was used to analyze the data. CAC 
and ∆Hagg values reported are the average of two or more repeat experiments for each amphiphile. 
 
Bacterial strains and growth conditions 
The Gram-positive bacterial strains used in this study were Staphylococcus aureus subsp. 
aureus ATCC® 29213™, Enterococcus faecalis ATCC® 29212™, Bacillus cereus, and Streptococcus 
agalactiae J48. 122 The Gram-negative bacterial strains used were Escherichia coli ATCC® 25922™ and 
Pseudomonas aeruginosa ATCC® 27853™. All strains were grown in 1X Mueller-Hinton Broth at 37 °C 
for 12-24 h. For the MIC and combination studies, bacterial suspensions were prepared by diluting 
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overnight cultures to 5 x 106 CFU/mL in 2X Mueller-Hinton Broth (so that when amphiphile solutions are 
added, the final broth strength is 1X). 
 
Minimum inhibitory concentration and minimum bactericidal concentration 
The methods used to determine the MIC and MBC were performed as previously described and followed 
the standards set forth by the Clinical and Laboratory Standards Institute. 39,123 Briefly, compounds were 
serially diluted and 100 µL of each dilution were added to the wells of a 96-well flat-bottomed microtiter 
plate in triplicate. After adding 100 µL of the bacterial cell suspension, the plates were incubated at 37 °C 
for 72 h. The MIC of the compound was defined as the minimum concentration that resulted in visible 
inhibition of bacterial growth. In order to determine the MBC, a 100 µl aliquot from each triplicate well 
was grown on Todd-Hewitt agar and incubated for 24 h at 37 °C. The MBC was defined as the 
concentration of the compound that resulted in a 99.9% reduction of the bacterial CFU/mL. The MIC was 
considered to be bactericidal if the MBC was the same concentration or one concentration higher in the 
dilution series as the MIC. 120 
  
 Combination studies 
To determine if two amphiphiles act synergistically to kill E. coli or S. aureus, combination studies were 
performed using the checkerboard technique as described. 110 Amphiphiles with MIC values higher than the 
maximum concentration used (>250 µM) were excluded from the combination studies. The amphiphile 
concentrations used in the combination studies ranged from 1/16 to 2 x the MIC. Fifty microliters of each 
amphiphile dilution and 100 µL of the bacterial suspension were added to the wells of a 96-well flat-
bottomed microtiter plate. Control wells consisted of the bacterial suspension treated with media alone and 
bacteria treated with individual amphiphiles. Plates were incubated at 37 °C for 72 h. The FIC index was 
calculated using the following formula: FIC  = FICA+ FICB = A / MICA + B/MICB. A and B are the MIC 
values of compound A and compound B when combined, and MICA and MICB are the MIC of compound 
A and B alone. 110 A combination was considered to be synergistic if the FIC was less than 0.5; a 
combination was considered indifferent with an FIC of 0.5-4; and a combination was considered 
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antagonistic with an FIC > 4. The FIC indices of synergistic combinations were confirmed in two separate 
experiments.  
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Chapter 3: Antibacterial and colloidal properties of single tailed amphiphiles 
  
3.1 Introduction  
The presence of antibacterial resistant pathogens, especially in a hospital setting, calls for the development 
of novel antibacterial agents. 1,10,12,124 Compounds that target essential bacterial structures, such as the 
bacterial cell membrane and proteins involved in transcription, hinder the development of resistance. 40 
Amphiphiles, compounds with at least one hydrophilic head group and hydrophobic tail, are widely 
hypothesized to disrupt the bacterial cell membrane and have promise as antibacterials.  35,36,38-40,62 
 
Over the past few decades, a broad spectrum of antibacterial amphiphiles with variations in composition, 
number, and spacing of head group(s); number and length of tail(s); and counter ion(s) have been 
synthesized. 35-39,48-59,61,62 In a previous study, our research group synthesized novel bicephalic amphiphiles 
with modifications in tail length (12-18 carbons) and spacing between head groups attached to an aromatic 
ring (4-6 carbons). 39 Structure-activity studies demonstrated bicephalic compounds with tail lengths of 12-
14 carbons and 14-16 carbons are the most effective against Gram-positive and Gram-negative organisms, 
respectively. In addition, the amphiphiles with a 5-carbon spacer between head groups (2,4- or 3,5- 
substitution pattern around an aromatic ring) have better antibacterial activity than homologues with a 4- or 
6-carbon spacer. 39 Because of this, subsequent series of novel compounds synthesized by our research 
group have incorporated a 5-carbon spacer between head groups.  
 
A recent study conducted by our research group investigated the structure-activity trends of two series of 
triple-headed, double tailed amphiphiles with a 5-carbon spacer between head groups around an aromatic 
core (1,3,5- substitution pattern) with tail lengths ranging from 8-16 carbons. (Table 4). 60 The antibacterial 
activity of both series is affected by tail length, where the compounds with tail lengths of 12 carbons are the 
most effective (Table 4). 60 Compounds with tail lengths of less than or more than 12 carbons have 
decreased activity.  
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Amphiphiles with tail-length specificity typically follow this trend, where MIC decreases as tail length 
increases until an optimal tail length is reached. After this point, the MIC begins to increase with increasing 
tail length. 39,51,54,59,60 One study investigated the effect of tail length on three series of triple-headed, single 
tailed amphiphiles with modifications in linker composition (B1-B15, Table 4). These three series of 
amphiphiles have an optimal tail length of 20 or 22 carbons (Table 4). 51,57 For the two series with an 
optimal tail length of 20 carbons, the tail length trend was evident – the MIC values increase for 
compounds containing more or less than 20 carbons (Table 4). 51,57 
 
Amphiphile structure also affects the critical aggregation concentration (CAC). Plots of log(CAC) and tail 
length show a linear relationship, where the slope of the line is affected by amphiphile structure. The CAC 
values of triple-headed, single tailed amphiphiles have a modest dependence on tail length (Fig. 13). 51,125 
In comparison, single- and double-headed amphiphiles typically have CAC values with a greater 
dependence on tail length (steeper slope). 72  
 
The relationship between the CAC and the MIC can reveal information about the mechanism of action of 
an amphiphile. Multiple studies reported MIC values of amphiphiles that were below the CAC values 
(Table 4). 49-51,54,60A compound with a MIC below the CAC does not require aggregation to inhibit bacteria, 
likely eliminating detergent-driven lysis as a possible mechanism. 49-51,57 
 
In order to further investigate the effect of structure on colloidal and antibacterial properties of triple-
headed amphiphiles, novel single tailed amphiphiles were synthesized. The triple-headed, single tailed 
amphiphiles contain two trimethylammonium head groups (M-1,1, series) and one 
alkyldimethylammonium head group attached to one tail ranging in length from 8-22 carbons (1-8) (Fig. 
13). Some of these amphiphiles were bactericidal against a broad spectrum of Gram-positive and Gram-
negative bacteria and are potential drug candidates for further antibacterial and toxicity studies.  
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3.2 Results and Discussion 
Synthesis2  
Each of the amphiphiles in this study was prepared by two subsequent Menshutkin reactions (Scheme 2). 
To prepare the M-1,1 (1-8) series, 1,3,5 trisbromomethylbenezene was reacted with two equivalents of 
trimethylamine resulting in intermediate 9. Selective reaction at just two of the three equivalent benzylic 
positions was aided by the decreased solubility of the desired products, which precipitate from the reaction 
mixture upon formation. Filtration of the reaction mixture followed by subsequent washes with a solution 
of acetone and ethanol yields intermediate 9. Substitution of the remaining benzylic bromide on 9 was 
accomplished using a slight excess of dimethylalkylamine (NMe2(CH2)n-1CH3, where n = 8, 10, 12, 14, 16, 
18, 20, or 22) in ethanol at reflux producing the series of amphiphilic products 1-8. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Section modified from Marafino, J. N. "Colloidal and Biological Properties of Triscationic Amphiphiles 
with One or Two Tails" (2014). Masters Theses, 2014 - Paper 7. 
http://commons.lib.jmu.edu/master201019/7	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Scheme 2. Synthesis of triple-headed, single-tailed amphiphiles. 
 
1,  R=C
8
H
17  
(M-1,1,8) 
2,  R=C
10
H
21 
(M-1,1,10) 
3,  R=C
12
H
25
 (M-1,1,12) 
4,  R=C
14
H
29
 (M-1,1,14) 
5,  R=C
16
H
33
 (M-1,1,16) 
6, R=C
18
H
37
 (M-1,1,18) 
7, R=C
20
H
41
 (M-1,1,20) 
8, R=C
22
H
45
 (M-1,1,22) 
Figure 13. Structure of M-1,1,n amphiphiles. Amphiphiles are named as follows: M-n,n,n 
where M refers to the Mesitylene core, and n represents the number of hydrocarbons in the 
tail; a number indicates the number of carbon atoms in the alkyl group of a dimethylalkyl 
ammonium (e.g., 1 = trimethylammonium; 8 = octyldimethylammonium).  
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Critical aggregation concentration  
The M-1,1, series exhibit a decrease in CAC as tail length increases, where a linear plot of log(CAC) versus 
tail length follows the equation:  
log(CAC) = A – Bn     (1) 
where A and B are constants and n is the number of carbons in each hydrocarbon tail (Table 5, Fig. 14). 
61,70,116 The plot of log(CAC) versus tail length indicates moderate dependence of CAC on tail length 
(B=0.16) and is consistent with other reports on triple-headed, single tailed amphiphiles. 51,125  
 
 
Antibacterial activity   
The MIC values of 1-8 were determined for 
four Gram-positive strains (Bacillus cereus, 
Enterococcus faecalis, Staphylococcus 
aureus, Streptococcus agalactiae) and two 
Gram-negative strains (Escherichia coli, 
Pseudomonas aeruginosa) (Table 6, Fig. 
15). For the M-1,1 series, compound 6 (M-1,1,18) has the lowest MICs (2-125 µM) for all tested strains 
(Table 6, Fig. 15). The MIC values of 6 (M-1,1,18) are lowest for S. agalactiae (2 µM) and highest for P. 
aeruginosa (125 µM). Reduced activity against Gram-negative strains is likely due to the presence of an 
additional outer membrane, which hinders the passage of extracellular molecules. P. aeruginosa especially 
is difficult to kill due to expression of selective porins and overproduction of drug efflux pumps. 27 
M-1,1 
Compound (#) 
Tail Length 
(n for M-1,1,n) CAC [mM] ∆Hmic (kJ/mol) ∆Gmic (kJ/mol) -T∆Smic (kJ/mol) 
4 14 21 -10 -20 -10 
5 16 11 -12 -22 -10 
6 18 5.0 -22 -24 -2.4 
7 20 2.0 -28 -26 1.6 
8 22 0.99 -33 -28 5.1 
Table	  5.	  CAC,	  ∆Hagg,	  ∆Gagg,	  and	  -­‐T∆Sagg	  for	  the	  M-­‐1,1	  series.	  Experiments	  were	  performed	  at	  37°C.	  	  
y = -0.1686x + 3.7068 
-0.5 
0.0 
0.5 
1.0 
1.5 
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g 
[C
A
C
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m
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)]
 
tail length (n for CnH2n+1) 
Figure 14. Plot of log(CAC) versus tail length for the M-1,1 
series. The slope of the line is given.  
Table 5. CAC, ∆Hmic, ∆Gmic, and T∆Smic for the M-1,1 series. 
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Compounds 5 (M-1,1,16) and 7 (M-1,1,20) have similar activity to 6 (M-1,1,18), varying in MIC values for 
the majority of organisms by a two-fold difference at most (Table 6). 
 
In addition to determining the MIC values for all compounds, the minimum bactericidal concentration 
(MBC) values were determined for compounds with low MICs (4-7) by the spread-plate method. The 
MBCs of compounds 4-7 were equivalent to MIC values, indicating these compounds kill bacteria at low 
concentrations.  
 
The antibacterial activity of the M-1,1 series is dependent on tail length, as demonstrated by the trend that 
the MICs decrease with increasing tail length until an optimal tail length is reached (Table 6, Fig. 15). The 
optimal tail lengths for three of the Gram-positive organisms are 18- and 20- carbons (compounds 6, 7), 
which have equivalent MIC values (Table 6, Fig. 15). The 18-carbon tailed compound (6) had the lowest 
MIC values for S. agalactiae and the two Gram-negative organisms (Table 6, Fig. 15). The MIC values of 
the longer tailed compound (8) increase for all tested organisms. This phenomenon is widely reported and 
is most likely explained by a balance between the solubility and hydrophobicity of the compound. 38-
40,50,51,54,57,59 Amphiphiles with longer tails are more effective at interacting with the hydrophobic 
phospholipid bilayer in the bacterial cell membrane. However, compounds with low solubility can form 
aggregates in solution and have decreased efficacy against bacteria. 50,51  
Table 6. MIC values (µM) of amphiphiles from the M-1,1,n and M-1,n,n series, where n represents the number of 
carbon atoms in the alkyl group of a dimethylalkyl ammonium. *The MIC values of M-1 series were determined in 
a previous study and were included for comparison. 
60 
G
+
 = Gram-positive; G
-
 = Gram-negative. 
Compound Tail length        (n for CnH2n+1) 
B. cereus (G+) E. faecalis (G+) S. agalactiae (G+) S. aureus (G+) E. coli (G-) P. aeruginosa (G-) 
1 8 >250  >250  >250  >250  >250  >250  
2 10 125 250 125 >250 >250 >250 
3 12 63 250 125 63 >250 >250  
4 14 16 31 16 63 250 >250 
5 16 4 8 4 31 31 >250 
6 18 4 4 2 16 16 125 
7 20 4 4 4 16 31 250 
8 22 >250 >250 >250  >250 63  >250 
10 8 >250 >250 >250 >250 >250 >250 
11 10 8 8 4 16 125 250 
12 12 2 2 2 2 4 16 
13 14 4 4 2 8 8 125 
14 16 16 32 8 16 63 >250 
M
-1
,1
,n
 
M
-1
,n
,n
* 
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Figure 15. Effect of tail length on the MIC for the M-1,1 series. # = MIC > 250 µM. G
+
 = 
Gram-positive; G
-
 = Gram-negative. 
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Comparison of colloidal and antibacterial properties of single tailed and double tailed amphiphiles  
In order to determine the effect of number of tails on CAC and MIC, results from a previous study on 
triple-headed, double tailed amphiphiles analogous in structure to the single tailed M-1,1 compounds were 
compared to the results from the current study (Tables 3.1-3.4). 60 Overall, the double tailed compounds 
have lower MIC and lower CAC values, when compared to the single tailed counterparts. In addition, the 
CAC values of the double tailed amphiphiles have a greater dependence on tail length (Table 7).  
 
The most effective compound from the double-tailed M-1 series [12 (M-1,12,12)] has a two to eightfold 
decrease in MICs against the majority of organisms compared to the MICs of compound 6 (M-1,1,18) 
(Table 6). 60 The double-tailed compound 12 (M-1,12,12) also has a lower CAC than the single-tailed 
compound 6 (M-1,1,18), indicating 12 is less soluble (Table 7). When comparing the MIC and CAC values 
of double and single tailed amphiphiles with equivalent tail length (e.g. M-1,1,14 and M-1,14,14), the 
double tailed amphiphiles have better overall antibacterial activity and lower solubility (lower CAC) 
(Tables 6,7).  
 
When comparing the total number of carbons in the tail(s) (e.g. M-1,8,8 and M-1,1,16), the double tailed 
compounds have higher CAC values than single tailed analogues (Table 7). The distribution of 
hydrocarbon groups across two tails increases the solubility of compounds, resulting in a higher CAC for 
double tailed amphiphiles.  
 
Antibacterial trends concerning the effect of total number of carbons in the tail(s) are not as apparent. 
When examining compounds with 16 carbons total in the tail(s), single tailed compound 5 (M-1,1,16) is 
much more effective than double tailed 10 (M-1,8,8) (Tables 6,7). In contrast, the antibacterial activity of 
the compounds with 20 total carbons in the tail(s) [7 (M-1,1,20) and 11 (M-1,10,10)] is approximately 
equivalent (Tables 6,7). Since the tail length did not exceed 22 carbons for the M-1,1 series, the efficacy of 
analogues with more than 22 carbons total in the tail(s) were not compared. However, comparisons of the 
two sets of compounds with equal number of carbons in the tail(s) (16 total carbons) indicate single tailed 
compounds with moderate tail length (M-1,1,16) are more effective than double tailed analogues with short 
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tails (M-1,8,8). When the tail length(s) of both single tailed and double tailed compounds were relatively 
moderate in length (10 carbons for double tailed and 20 carbons for single tailed), the antibacterial 
activities were nearly equivalent (Tables 6,7).  
 
Comparison of these two series indicates antibacterial and colloidal properties are affected by both length 
of tail and number of tail(s). The number of tails affects the geometry of amphiphiles, which may also 
explain differences in activity of the single tailed and double tailed amphiphiles. Triple-headed, one tailed 
amphiphiles have a cone shape, whereas double tailed amphiphiles have more of a cylindrical shape. 
Phospholipids are cylindrical as well, which may explain the enhanced activity of the double tailed 
amphiphiles. 126 This similarity in geometry may contribute to the insertion of double tailed amphiphiles 
into the phospholipid bilayer. 
 
 
 
 
 
Table 7. Comparison of CAC (mM) and MIC values (µM) of amphiphiles that vary in number of tails. 
The M-1,1,n series is single tailed, and the M-1,n,n series is double tailed, where n represents the number 
of carbons in each alkyl group attached to a dimethlylalkyl ammonium. The CAC and MIC values of the 
M-1,n,n series were determined in a previous study and included for comparison.
59 
G
+
 = Gram-positive; 
G
-
 = Gram-negative. *The CAC of M-1,8,8 was not determined but can be estimated to be approximately 
46 mM based extrapolation of data from the other amphiphiles in this series. 
  
Compound # 
Tail Length 
(n,n for M-1,n,n      
or n for M-1,1,n) 
Total # carbons 
in tail(s) CAC (mM) 
  
    (G+) (G-)   
  Most effective 
amphiphiles 
from each series 
12 12,12 24 2.5 2 4-16   
  6 18 18 5 2-16 16-125   
  Comparison of 
amphiphiles 
with equal # 
carbons per 
tail(s) 
13 14, 14 28 0.61 2-8  8-125    
  4 14 14 21 16-63  250->250    
  14 16,16 32 0.16 8-31  63->250   
  5 16 16 11  4-31 31->250    
  Comparison of 
amphiphiles 
with equal # 
total carbons in 
tail(s) 
10 8,8 16 ≈46 >250 >250   
  5 16 16 11 4-31 31->250   
  11 10,10 20 12 4-16 125-250   
  7 20 20 2 4-16 31-250   
               
Range of  MIC values (µM)  
!
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Combination Studies  
A previous study on the two series of triple-headed, double tailed amphiphiles identified three synergistic 
combinations consisting of two compounds from one or both series. 60 To determine if single tailed and 
double tailed amphiphiles are synergistic, studies of binary combinations were performed with E. coli and 
S. aureus. The fractional inhibitory concentration (FIC) was used to assess the interactions between two 
compounds. A combination was considered to be synergistic if the FIC<0.5, or if the MICs of each 
amphiphiles decreased more than fourfold. 110 Theoretically, a twofold decrease in the MIC would be 
considered a synergistic combination. However, a more conservative threshold of FIC<0.5 is widely used 
to allow for a one well dilution error in the assay. 127 None of the combinations involving at least one M-1,1 
compound have FICs<0.5 (Fig. S1). However, several combinations had FIC values <1.0, suggesting these 
combinations could be considered synergistic. The broad-spectrum efficacy of these compounds could be 
useful in a clinical setting potentially for the treatment of bacterial infection, disinfection of contaminated 
equipment, or prevention of bacterial colonization on hospital surfaces. 
 
3.3 Conclusions 
The effect of amphiphile structure on colloidal and antibacterial characteristics was investigated for a novel 
series of triple-headed, single tailed amphiphiles. A linear plot of log(CAC) and tail length indicates the 
CAC of the M-1,1 amphiphiles is moderately dependent on tail length. The antibacterial activity of these 
compounds is also dependent on tail length as indicated by the low MIC values of the 18 and 20 carbon 
tailed derivatives (6, 7). The MIC values of compound 6 were in the single digit micromolar range for three 
Gram-positive organisms and ranged from 16-125 µM for S. aureus, E. coli, and P. aeruginosa. 
Comparison of these single tailed compounds to double tailed compounds from a previous study indicated 
colloidal and antibacterial activity is affected by the number and length of tail(s). The broad spectrum 
efficacy of these compounds could be useful for the treatment of bacterial infection or sterilization of 
contaminated medical equipment.  
 
 
 
 
	  	  
43	  
3.4 Methods & Materials  
 
Synthesis  
Synthesis of intermediate 93 
1,3,5-tribromomethylbenezene (1.0 g, 2.8 mmol) was dissolved in acetone at room temperature in a round 
bottom flask (RBF). The solution was cooled on an ice bath for 30 minutes, equipped with a stir-bar, and 
attached to an addition funnel. An ethanolic trimethylamine solution (1.2 mL, 5.6 mmol) was dissolved in 
acetone and cooled on an ice bath for 30 minutes. The trimethylamine solution was added drop-wise to the 
stirring solution of 1,3,5-tribromethylbenzene. The reaction was run overnight, and warmed slowly to room 
temperature. A white precipitate containing a mixture of 9 (M-1,1) and side product formed. The crude 
reaction mixture was vacuum filtered and resuspended in a solution of acetone and ethanol (100:3), heated 
to 60°C, stirred for at least 30 minutes, vacuum filtered, and dried under vacuum to produce 9 (M-1,1) 
(856.4 mg, 64.05%, white solid). 
 
Synthesis of 1-8: General Protocol A3 
9(M-1,1) was added to a two neck round bottom flask and dissolved in ethanol. The flask was equipped 
with a stir bar and attached to a water-cooled condenser. Alkyl amine (NMe2(CH2)n-1CH3,where n = 8, 10, 
12, 14, 16, 18, 20, or 22) was added slowly to the flask using a syringe. The reaction was heated to 80°C 
and run overnight at reflux. Volatile materials were removed under a flow of N2 (g). The resulting crude 
solid was resuspended in acetone, vacuum filtered, and dried in under vacuum to yield the solid amphiphile 
product (1-8).   
 
Isothermal Titration Calorimetry3 
CAC and ∆Hmic were determined using a Nano-ITC (TA-Instruments). Prior to each experiment, the sample 
cell was washed with dH2O (300 mL), ethanol (100 mL), dH2O (300 mL) and nanopure water (200 mL). 
Next, 950 µL of nanopure water was added to the sample cell. A concentrated aqueous solution (>>CAC) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  Sections modified from Marafino, J. N. "Colloidal and Biological Properties of Triscationic Amphiphiles 
with One or Two Tails" (2014). Masters Theses, 2014 - Paper 7. 
http://commons.lib.jmu.edu/master201019/7	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of amphiphile was prepared and equilibrated at 37°C. A 250 µL syringe was filled with the aqueous 
solution, and loaded into the Nano ITC. Multiple single injections in aliquots of 5 µL were injected into the 
sample cell with time intervals varying from 300s to 1400s. Samples were continuously stirred (300 rpm) 
throughout the titration. The Nano-Analyze program (TA-Instruments) was used to analyze the data. CAC 
and ∆Haggregate values reported are the average of two or more repeat experiments for each amphiphile. 
 
Bacterial strains and growth conditions 
The Gram-positive bacterial strains used in this study were Staphylococcus aureus subsp. 
aureus ATCC® 29213™, Enterococcus faecalis ATCC® 29212™, Bacillus cereus, and Streptococcus 
agalactiae J48. 122 The Gram-negative bacterial strains used were Escherichia coli ATCC® 25922™ and 
Pseudomonas aeruginosa ATCC® 27853™. All strains were grown in 1X Mueller-Hinton Broth at 37 °C 
for 12-24 h. For the MIC and combination studies, bacterial suspensions were prepared by diluting 
overnight cultures in 2X Mueller-Hinton Broth to 5 x 106 CFU/mL.  
 
Minimum inhibitory concentration and minimum bactericidal concentration 
The methods used to determine the MIC and MBC were performed as previously described and followed 
the standards set forth by the Clinical and Laboratory Standards Institute. 39,123 Briefly, compounds were 
serially diluted and 100 µL of each dilution were added to the wells of a 96-well flat-bottomed microtiter 
plate in triplicate. After adding 100 µL of the bacterial cell suspension (5 x 106 CFU/mL), the plates were 
incubated at 37 °C for 72 h. The MIC of the compound was defined as the minimum concentration that 
resulted in visible inhibition of bacterial growth.  
 
The MBC was determined for compounds 4-6. In order to determine the MBC, a 100 µl aliquot from each 
triplicate well was grown on Todd-Hewitt agar and incubated for 24 h at 37 °C. The MBC was defined as 
the concentration of the compound that resulted in a 99.9% reduction of the bacterial CFU/mL. The MIC 
was considered to be bactericidal if the MBC was the same concentration or one concentration higher in the 
dilution series as the MIC. 120 
Combination studies 
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To determine if two amphiphiles act synergistically to kill E. coli or S. aureus, combination studies were 
performed using the checkerboard technique previously described. 60 Binary combinations consisted of M-
1,1 compounds combined with another single tailed compounds or double tailed compounds from a previus 
study. 60Amphiphiles with MIC values higher than the maximum concentration used (>250 µM) were 
excluded from the combination studies. The amphiphile concentrations used in the combination studies 
ranged from 1/16 to 2 x the MIC. Fifty microliters of each amphiphile dilution and 100 µL of the bacterial 
suspension were added to the wells of a 96-well flat-bottomed microtiter plate. Control wells consisted of 
the bacterial suspension treated with media alone and bacteria treated with individual amphiphiles. Plates 
were incubated at 37 °C for 72 h. The FIC index was calculated using the following formula: FIC  = FICA+ 
FICB = A / MICA + B/MICB. A and B are the MIC values of compound A and compound B when 
combined, and MICA and MICB are the MIC of compound A and B alone. 110 A combination was 
considered to be synergistic if the FIC was less than 0.5; a combination was considered indifferent with an 
FIC of 0.5-4; and a combination was considered antagonistic with an FIC > 4. The FIC indices of 
synergistic combinations were confirmed in two separate experiments. 	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Chapter 4: Cytotoxicity studies on amphiphiles 
 
 
4.1 Introduction 
 
Drug development is a tedious task, often taking 12-15 years of research and development and costing 800 
million to two billion dollars. 4 The development process involves identifying effective compounds in in 
vitro or in silico studies, testing the safety of drug candidates in preclinical safety studies using in vitro cell 
culture and animal models, and then moving forward to clinical studies.  4,88 In preclinical and clinical 
safety studies, the therapeutic index (TI) is used to compare the effectiveness of a compound to its toxicity. 
The TI is the concentration of drug that is considered to be safe with a particular model divided by the 
concentration of drug required to inhibit the target of interest. A larger TI indicates the drug candidate is 
more selective for the target and presumably, safer. 4,88 Although the TI is widely used in toxicity studies, 
no universal regulations concerning the interpretation of the TI exist. It is impossible to define a universal 
standard for the TI, because it will vary based on the phase of the study, model used, and properties of the 
drug candidate. Typically, the TI is interpreted in a case-by-case basis by experts who assess the drug’s 
safety after thorough investigation of the drug during and after multiple preclinical studies and clinical 
studies. 88 Clinical studies must demonstrate the compound is safe and effective before the drug is approved 
by the FDA and available for prescription. 4  
 
Early safety studies on antibacterial amphiphiles utilize eukaryotic cell lines or red blood cells (RBCs) to 
identify potential leads that are both safe and effective. 36-38,49,51 The hemocomptability (safety to RBCs) of 
drug candidates can be investigated in in vitro hemolysis studies and can identify potential drug leads. 
Understanding a compound’s interaction with blood cells is necessary before administering the drug to 
humans. Even if a compound’s intended use does not involve intravenous injection, a drug may still be 
absorbed into the blood stream after oral or aerosol administration.  128  
 
In toxicity studies, sheep blood is often used as model for human blood because of similarities in red blood 
cell production and development. 129 The TI for hemolysis studies is computed by dividing the effective 
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concentration that results in 50% hemolysis (EC50) or 10% hemolysis (EC10) by the compound’s minimum 
inhibitory concentration (MIC). 37,49,51 Although hemolysis assays are a cost-effective and simple  
method to identify potential drug leads, the assay is limited by the fragility of the red blood cells. Proper 
storage and processing of red blood cells is essential to ensure cell viability and avoid hemolysis caused by 
mechanical or temperature stress. 130 In addition, the presence of nonaqueous cosolvents in the blood can 
affect the spectrophotometer readings, so red blood cells should be studied in pure aqueous solvent, further 
increasing their susceptibility to hemolysis. 131 Still, if the blood cells are maintained properly, hemolysis 
studies can be used to identify potential non-toxic drug leads.   
 
This study investigated the cytotoxicity of three novel series of amphiphiles that were antibacterial against 
a broad spectrum of pathogens. 60 All three series of amphiphiles consist of three cationic head groups 
attached to a mesitylene core (M). For the M-P and M-1 series, two of the head groups are 
dimethylalkylammonium groups with hydrocarbon tails consisting of 8-16 carbons. The third head group is 
either pyridinium (M-P) (Fig. 16c) or trimethylammonium (M-1) (Fig. 16b). For the M-1,1 series, one of 
the head groups is dimethylalkylammonium with a single, linear hydrocarbon tail consisting of 8-22 
carbons attached. The other two head groups are trimethylammonium groups (M-1,1) (Fig. 16a).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1,  R=C8H17  (M-1,1,8) 
2,  R=C10H21 (M-1,1,10) 
3,  R=C12H25 (M-1,1,12) 
4,  R=C14H29 (M-1,1,14) 
5,  R=C16H33 (M-1,1,16) 
6, R=C18H37 (M-1,1,18) 
7, R=C20H41 (M-1,1,20) 
8, R=C22H45 (M-1,1,22) 
 
 
10,  R=C8H17  (M-1,8,8) 
11,  R=C10H21 (M-1,10,10) 
12,  R=C12H25 (M-1,12,12) 
13,  R=C14H29 (M-1,14,14) 
14,  R=C16H33 (M-1,16,16) 
 
 
15,  R=C8H17  (M-P,8,8) 
16,  R=C10H21 (M-P,10,10) 
17,  R=C12H25 (M-P,12,12) 
18,  R=C14H29 (M-P,14,14) 
19,  R=C16H33 (M-P,16,16) 
 
 
a b c 
Figure 16. Structure of (a) M-1,1 (b) M-1 and (c) M-P series.  
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4.2 Results & Discussion 
Effective concentration and therapeutic index 
The percentage of hemolysis for compounds with MIC (minimum inhibitory concentration) values ranging 
from 1-250 µM was determined (Fig. 17). The concentration of amphiphile that resulted in 50% hemolysis 
(EC50) was used to calculate the therapeutic index (TI). The TI of each compound was calculated for 
representative Gram-positive and Gram-negative pathogens (S. aureus and E. coli) by dividing the EC50 by 
the MIC (Table 8). Several amphiphiles have therapeutic indices greater than two, meaning the 
concentration considered to be safe with red blood cells was higher than the MIC (Table 9) 
 
Notably, compound 15 (M-P,10,10) has TI values of 65 and 8.1 against S. aureus and E. coli, respectively 
(Table 9). The selectivity of M-
P,10,10 for S. aureus and E. coli  is 
comparable to the reported 
therapeutic indices  of cationic 
amphiphiles from other studies, 
ranging from 10-171 (Table 8, 
Table 9). 37,49 The TI of 15 (M-
P,10,10) for S. aureus is also 
comparable to the in vitro TI of 
tobramycin for the Gram-negative 
pathogen P. aeruginosa (TI = 70). 
In comparison to other bacteria, P. 
aeruginosa is intrinsically resistant 
to many antibiotics, typically 
requiring a larger concentration of 
antibiotic to be killed. Still, the 
large TI of M-P,10,10 for S. aureus 
!! !! MIC (µM) !!
!! EC50 (µM)  
P. aeruginosa 
(G-) Therapeutic Index 
Tobramycin 140 2 70 
!! !!
MIC  (µM)  
!! !! !!
!! !! Therapeutic Index  
Compound EC50 (µM)  
S. aureus 
(G+) 
E. coli  
(G-) 
S. aureus 
(G+) 
E. coli   
(G-)  
4 (M-1,1,14) 130 63 250 2 0.5  
5 (M-1,1,16) 9.3 31 31 0.3 0.3  
6 (M-1,1,18) 4.3 16 16 0.27 0.27  
7 (M-1,1,20) 4.3 16 31 0.27 0.14  
11 (M-1,10,10) 130 16 125 8.1 1  
12 (M-1,12,12) 8.6 2 4 4.3 2.2  
13 (M-1,14,14) 3.8 8 8 0.475 0.5  
14 (M-1,16,16) 4.6 16 63 0.2875 0.07  
15 (M-P,10,10) 130 2 16 65 8.1  
16 (M-P,12,12) 9.3 2 4 4.7 2.3  
17 (M-P,14,14) 4.3 4 16 1.1 0.26  
18 (M-P,16,16) 4.3 32 125 0.13 0.03  
!! !! !! !! !! !! !!
Table 8. Comparison of minimum inhibitory concentration (MIC), 
hemolytic effective concentration (EC), and therapeutic indices of  
amphiphiles from this study and tobramycin. Bold values indicate 
compounds with therapeutic indices > 2. ND= Not determined. G(+) = 
Gram-positive.; G(-) = Gram-negative; EC50 = Effective concentration 
that resulted in 50% hemolysis.  
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suggests this compound has potential for treatment of S. aureus infection or disinfection of contaminated 
surfaces.  
 
Although compound 15 (M-P,10,10) is not the most effective amphiphile against the Gram-negative E. 
coli, it has the highest TI values for E. coli and S. aureus (Table 8). When assessing effectiveness and 
safety, compound 15 (M-P,10,10) is a candidate for further investigation in safety studies with epithelial 
cell lines. Worth noting, several compounds have therapeutic indices ranging from 2-8, including 10 (M-
1,10,10), 11 (M-1,12,12) and 16 (M-P,12,12), and will also be investigated in additional toxicity studies 
(Table 8).  
 
Figure 17. Dose-response curves for (a) M-1,1 (b) M-1 (c) M-P and  (d) Tobramycin. Hemolysis 
assays were repeated three times for amphiphiles and twice for tobramycin. The average percent 
hemolysis is represented for each amphiphile. Error bars indicate the standard deviation of the 
average percentage. 	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Structure-hemolytic activity trends 
Both length and number of tail(s) has an effect on hemolysis. Generally, the hemolytic activity of a 
compound increases as hydrophobicitiy increases. All three series of amphiphiles follow the trend that 
hemocytoxicity increases with increasing tail length, which is consistent with other studies (Table 8, Fig.  
17).  37 When comparing the effect of number of tails on cytotoxicity overall, the single-tailed series (M-1,1) 
has higher EC50 values than the double-tailed series (M-1 and M-P) (Table 8). However, when comparing 
compounds with equal total number of carbons in the tail(s) – 7 (M-1,1,20), 10 (M-1,10,10), and 15 (M-
P,10,10) – the double tailed compounds 10 and 15 had higher EC50 and TI values than the single tailed 7 
Representative Compound 
[tail length(s)] 
MIC (µM) Hemolysis Therapeutic index 
(G+) (G-) EC (µM) Method (G+) (G-) Reference 
Cationic Triple-headed, 
double tailed [10,10] 
2 16 130 EC50, sheep blod 65 8.1 This work  
Anionic Triple-headed, 
double tailed [10,10] 
3 NA 480 EC10, sheep blood  171 NA 
[49] 
Falkinham, 
et al. 
Tuberculosis 
2012, 92, 
173-181.  
Double-headed, double 
tailed [12,12], n=6 
13 10 128 EC50, human blood 13 10 
[37] Hoque, 
et al. 
Langmuir 
2012, 28, 
12225-12234 
Table 9: Comparison of minimum inhibitory concentration (MIC), hemolytic effective concentration (EC), and 
therapeutic indices of  amphiphiles from this study and two other studies. Representative amphiphiles had the highest 
therapeutic index within a particular series. MIC values represent MICs for S. aureus and E. coli for this work and the 
double-headed compound and Mycobacterium avium for the anionic triple-headed compound.  (G+) = Gram-positive; 
(G-) = Gram-negative.  
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(M-1,1,20) (Table 8). The composition of the third head group did not significantly affect hemolytic 
activity (M-P and M-1 series) (Table 8). 
 
4.3 Conclusions 
The cytotoxicity of three novel series of amphiphiles was determined with sheep red blood cells, and the 
effect of amphiphile structure on hemolytic activity was investigated. Increasing hydrophobicity of 
compounds contributed to increases in cytotoxicity. Worth noting, compound 15 (M-P,10,10) had high 
selectivity for S. aureus (TI=65) and E. coli (TI=8.1). The TI of 15 (M-P,10,10) for S. aureus is indirectly 
comparable to the TI of tobramycin for Gram-negative P. aeruginosa (TI = 70). Compound 15 and several 
other compounds with TI values >2 may have promise as nontoxic drug candidates and will be investigated 
in additional cytotoxicity studies.  
 
4.4 Methods	   
Hemolysis assay 
For the hemolysis assay, defibrinated sheep blood (Fisher Scientific) and buffers were warmed to 37º C. 
Red blood cells were suspended in Ringer’s solution (7.2 g/L NaCl; 0.37 g/L KCl; 0.17 g/L CaCl2) and 
centrifuged at 1500 RCF. Supernatant containing lysed cells and plasma was disposed of, and pelleted red 
blood cells were resuspended in PBS. Wash steps were repeated until the supernatant was clear. Red blood 
cells resuspended in PBS were counted using a hemacytometer and diluted to 2 x 108 cells/ml in PBS. Five 
hundred microliters of the red blood cells (108 cells/mL) were then incubated with 500 µL of amphiphile 
(diluted 1:2 with PBS) at concentrations ranging from 2-250 µM. Water was used as a positive control for 
hemolysis and PBS was used as a negative control. The samples were incubated for 20 min at 37º C. The 
samples were then centrifuged at 1500 RCF for 20 min. Triplicates of 100 µL supernatant were pipetted 
into a 96-well plate, and the OD450 values were recorded using a microtiter plate reader. The averages of 
each triplicate were calculated and the percent hemolysis was determined using the formula: 
 % hemolysis = OD450 Compound – OD450 PBS      
               OD450  Water  – OD450 PBS              
 
where OD450 Compound is the OD of the sample incubated with an amphiphile; OD450 PBS is the negative 
control to account for spontaneous lysis; and OD450 Water is the positive control for hemolysis.  
X 100 
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Hemolysis assays were repeated three times for each amphiphile and twice for tobramycin. The average 
percentage of hemolysis and standard deviation were calculated.  
 
Statistical Analysis  
In order to determine the EC50, the Gauss-Newton method for nonlinear regression was used to estimate the 
parameters for the following drug response model: 
  
where xi is the dosage level at level i and y is the response variable as a percentage of maximum possible 
responsiveness. β0 is the expected response at dose saturation, β2 is the concentration that produces a half-
maxima response, and β1 determines the slope. Nonlinear regression analyses were performed using SAS 
version 9.3. SAS code for the Gauss-Newton method is included in the appendix.  
  	   	  
       β0 yi= 
1+(xi/β2)β1 
β0 –  + εi 
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Chapter 5: Conclusions  
Synthesis and colloidal properties  
Three novel series of triple-headed amphiphiles were synthesized, and the effect of tail length (8-22 
carbons), number of tails (1-2), and head group composition (trimethyalammonium or pyridinium) on 
colloidal and antibacterial properties was investigated. Overall, the critical aggregation concentration 
(CAC) values are higher for single tailed amphiphiles, indicating the single tailed amphiphiles are more 
soluble in solution. The log(CAC) decreases linearly with increasing tail length for all three series with a 
moderate dependence on tail length for single tailed amphiphiles (M-1,1 series) (slope = -0.16) and cogent 
dependence on tail length for the double tailed amphiphiles (M-P and M-1 series) (slope = -0.3). The CAC 
was not affected by modification of the third head group from trimethylammonium (M-1 series) to 
pyridinium (M-P series) for the double tailed compounds. 
 
Antibacterial activity  
The minimum inhibitory concentration (MIC) of compounds were determined for four Gram-positive and 
two Gram-negative organisms. The antibacterial activity of all three series is affected by tail length, as each 
series has one compound with an optimal tail length. For the double tailed series (M-P and M-1), 
compounds with two tails each consisting of 12 carbons are the most effective, with MICs ranging from 2-
16 µM. The single tailed series (M-1,1) has an optimal tail length of 18 carbons (MICs=2-125 µM). These 
optimal tail lengths are consistent with amphiphiles from other studies, where double-tailed compounds 
typically have an optimal tail length between 12-16 carbons and tricephalic compounds have optimal tail 
lengths around 20 carbons. 35,39,49,54 
 
In addition to tail length, the number of hydrophobic tails plays a role in antibacterial activity. The most 
effective compounds from the double tailed series have lower MIC values than the most effective single 
tailed amphiphiles. However, when comparing single tailed and double tailed compounds with an 
equivalent number of total carbons in the tail(s), a trend is not as apparent. For example, when comparing 
compounds with 16 carbons total in the tail(s), the single tailed M-1,1,16 was much more effective than 
double tailed M-P,8,8. However, amphiphiles with 20 carbons in the tail(s) (M-1,1,20 and M-1,10,10) have 
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approximately equivalent MICs. Modification of the third head group from trimethylammonium to 
pyridinium did not impact antibacterial activity, with approximately equivalent MIC values for the M-P and 
M-1 series.  
 
These amphiphiles have broad-spectrum efficacy and have potential for the treatment of bacterial infection, 
sterilization of contaminated equipment, and the prevention of bacterial colonization on surfaces. The 
association of antibiotic-resistant pathogens with hospital-acquired infection demonstrates the need for new 
effective antibacterial drugs. The efficacy of antibacterial amphiphiles against antibiotic resistant 
pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), will be investigated by our 
research group. Compounds that inhibit MRSA and other antibiotic resistant pathogens could prove 
invaluable in healthcare facilities.   
In order to determine if combinations of amphiphile could enhance antibacterial activity, the interactions 
between binary combinations of M-1; M-1,1; and/or M-P amphiphiles were studied using the microbroth 
checkerboard method. Three synergistic binary combinations were identified, all of which consist of M-
P,12,12 combined with another double tailed amphiphile. These synergistic combinations decreased the 
MIC of M-P,12,12 to less than 1 µM with S. aureus.  
Other research groups have reported amphiphiles that act synergistically in vitro with other antibacterial 
agents, including antibiotics, ethanol and other amphiphiles. 38,62,132 In addition, one hospital study 
demonstrated that combination of amphiphiles with triclosan in antibacterial hand soap decreased the 
transmission of bacteria. 85Additional benefits of synergistic combinations of antibacterial agents include 
lower mortality rates when treating bacterial infection and decreased risk of the development of resistance. 
15,76-80,82 Synergistic combinations containing M-P,12,12 are strong candidates for further investigation 
concerning efficacy against MRSA and other pathogens. In addition, the interactions of M-P,12,12 and 
other antibacterial amphiphiles with antibiotics will be investigated by our research group. The use of 
synergistic combinations of amphiphiles and antibacterial drugs in a clinical setting could prove beneficial 
by increasing the spectrum of antibacterial agents and impeding the development of resistance.   
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Cytotoxicity  
Compounds were tested with red blood cells to identify compounds that may be hemocompatible. The 
safety of amphiphiles was assessed by determining the therapeutic index (TI) – defined as the EC50 divided 
by the MIC. A large TI is indicative of compounds that are presumably safer. M-P,10,10 has the largest TI 
for in vitro treatment of S. aureus (TI=65), which was comparable to the TI of tobramycin for the Gram-
negative pathogen P. aeruginosa (TI=70). In addition, several other compounds have TI values ranging 
from 2-8 (M-1,10,10; M-1,12,12; and M-P,12,12), suggesting these compounds may be hemocompitable. In 
order to continue the investigation of the safety of these compounds, toxicity tests with epithelial cell lines 
are in progress.  
 
Future studies and potential applications  
Several compounds with broad-spectrum antibacterial activity and large therapeutic indices were identified 
(M-P,10,10; M-P,12,12; M-1,12,12). The safety of these compounds will continue to be investigated in 
different models, including epithelial cell lines. Because of presence of antibiotic resistant organisms in 
hospitals, these compounds will also be tested individually and in combination with methicillin-resistant S. 
aureus (MRSA). In addition, activity against other pathogens including the influenza virus, fungi, and 
spore-forming bacteria will be explored by our research group.  
 
Several amphiphiles from this study have broad-spectrum activity against multiple pathogens and are 
nontoxic to red blood cells at concentrations greater than their MIC values. These compounds could play a 
role in combatting antibiotic resistance, especially as the development of novel antibiotics continues to 
decrease. The extensive antibacterial activity of these amphiphiles allows for a range of potential 
applications to be considered, including treatment of bacterial infection and sterilization of contaminated 
hospital equipment.  	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Appendix 
Supplemental Figure 
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Appendix 
SAS Code for Gauss-Newton Nonlinear regression: 
DATA m114; 
INPUT x y; 
datalines; 
2 0.316 
2 -0.23 
2 0.943 
4 .417 
4 0.230 
4 1.11 
8 0.189 
8 0.115 
8 .632 
16 1.04 
16 0 
16 0.790 
31.25 0.283 
31.25 0.574 
31.25 1.42 
62.5 8.11 
62.5 6.54 
62.5 6.793 
125 65.6 
125 22.6 
125 56.5 
250 102 
250 98.9 
250 92.6 
   ; 
run; 
PROC GPLOT DATA = m114; 
PLOT y*x; 
run; 
 
PROC NLIN DATA = m114 METHOD=GAUSS HOUGAARD; 
  PARAMETERS   
      a=0 to 100  
   b=2 to 250  
   c=1;  
    model y = a-(a/(1 +(x/b)** c)); 
OUTPUT out=nlinout predicted=pred r=res; 
run; 
symbol1 v=circle l=32  c = black; 
PROC GPLOT DATA=nlinout; 
PLOT res*pred / VREF=0; 
run; 	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